Amgen Q2 sales rise, but growth depends on Repatha and beyond
This article was originally published in Scrip
Executive Summary
Amgen executives didn't shed a lot of light during the company's second quarter earnings conference call on issues at the top of investors' minds: commercial expectations for PCSK9 inhibitor Repatha (evolocumab) and the strategy for growth beyond existing research and development programs.